Vaxcyte is a pre-revenue biotech burning cash with 4 consecutive earnings misses and quality scores well below minimum thresholds, but strong positive price momentum and a 91% analyst upside target reflect speculative optimism around its vaccine pipeline.
Thesis pillars
- Pipeline Upside Speculation→Stable
- Cash Burn Quality Deficit→Stable
- Earnings Miss Streak→Stable
- +1 more pillar — see the Why tab for full reasoning
Vaxcyte, Inc. (PCVX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $57.34: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 4.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 10%; Elevated put/call ratio: 4.71; Below-average business quality.
Vaxcyte is a clinical-stage vaccine company with no approved products, developing pneumococcal conjugate vaccine candidates — VAX-31, VAX-24, and VAX-XL — using the XpressCF™ cell-free protein synthesis platform exclusively licensed from Sutro Biopharma. VAX-31 entered adult... Read more
Sell if holding. Engine safety override at $57.34: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 4.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 10%; Elevated put/call ratio: 4.71; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.2/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.
About Vaxcyte, Inc.
About Vaxcyte, Inc.
Vaxcyte entered adult Phase 3 clinical trials for VAX-31, its 31-valent pneumococcal conjugate vaccine candidate, in December 2025, targeting the approximately $8 billion global pneumococcal vaccine market. The company reported a net loss of $766.6 million in 2025, up from $463.9 million in 2024, and held $2,442.6 million in cash and investments as of December 31, 2025. The FDA granted VAX-31 breakthrough therapy designation in November 2024 for prevention of invasive pneumococcal disease in adults and expanded that designation to include prevention of pneumonia in August 2025.
Vaxcyte has no approved products and generates no product revenue; it funds operations through equity and debt financing, having accumulated a deficit of $2.2 billion as of December 31, 2025. The pipeline centers on pneumococcal conjugate vaccines produced via the XpressCF cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc., with Lonza serving as primary contract manufacturer for drug substance and Thermo Fisher Scientific's Patheon unit committed to provide custom commercial fill-finish capacity at a Greenville, North Carolina facility under a long-term agreement of up to $1 billion. The company competes against Pfizer's Prevnar franchise (PCV13 and PCV20) and Merck's VAXNEUVANCE, Capvaxive, and Pneumovax 23 as the current standard-of-care PCVs. VAX-31 is designed to cover approximately 95% of invasive pneumococcal disease in U.S. adults aged 50 and older and 88% of pneumococcal pneumonia, spanning both currently circulating and historically prevalent serotypes.
Show full overview
The adult Phase 3 program now consists of three concurrent trials: OPUS-1, a pivotal non-inferiority trial with topline data expected in the fourth quarter of 2026; OPUS-2, evaluating concomitant administration with a high-dose influenza vaccine in pneumococcal-naïve adults aged 50 and older, initiated January 2026; and OPUS-3, evaluating VAX-31 in adults previously vaccinated with a lower-valency PCV, initiated February 2026, with OPUS-2 and OPUS-3 data expected first half of 2027. The OPA non-inferiority threshold in OPUS-1 is set at 0.667 following an FDA End-of-Phase 2 meeting — stricter than the 0.50 standard used in prior PCV approvals — and failure to meet this threshold would materially impair the adult indication.
See also: Healthcare · Biotechnology
From Vaxcyte, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-06-29Recent Developments — Vaxcyte, Inc.
Latest news
- NEWS 10 Health Care Stocks With Whale Alerts In Today’s Session — benzinga Jun 29, 2026 neutral
- NEWS Vaxcyte Announces First Patient Enrollment In Phase 1 Study Evaluating Group A Streptococcus Vaccine VAX-A1 — benzinga Jun 2, 2026 positive
- NEWS Top 3 Health Care Stocks You'll Regret Missing In May — benzinga May 26, 2026 positive
- NEWS Earnings Scheduled For May 6, 2026 — benzinga May 6, 2026 neutral
- NEWS Vaxcyte Q1 EPS $(2.30) Misses $(1.82) Estimate — benzinga May 6, 2026 negative
Generated 2026-06-30T00:04:05Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMpipelinePCV candidates10-K Item 1A: 'Our business is highly dependent on the success of our PCV candidates'
- HIGHSupplierSutro Biopharma10-K Item 1A: 'XpressCF® platform exclusively licensed from Sutro Biopharma, Inc.'
- HIGHSupplierLonza10-K Item 1: 'our contract manufacturer, Lonza, that we believe can facilitate an independent path to market'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $57.34: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 4.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 10%; Elevated put/call ratio: 4.71; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $53.44. Score 5.2/10, moderate confidence.
Take-profit target: $94.83 (+65.0% upside). Prior stop was $53.44. Stop-loss: $53.44.
Concentration risk — Supplier: Sutro Biopharma; Concentration risk — Supplier: Lonza; Quality below floor (1.2 < 4.0).
Vaxcyte, Inc. trades at a P/E of N/A (forward -7.6). TrendMatrix value score: 9.0/10. Verdict: Sell.
17 analysts cover PCVX with a consensus score of 4.3/5. Average price target: $109.
What does Vaxcyte, Inc. do?Vaxcyte is a clinical-stage vaccine company with no approved products, developing pneumococcal conjugate vaccine...
Vaxcyte is a clinical-stage vaccine company with no approved products, developing pneumococcal conjugate vaccine candidates — VAX-31, VAX-24, and VAX-XL — using the XpressCF™ cell-free protein synthesis platform exclusively licensed from Sutro Biopharma. VAX-31 entered adult Phase 3 trials in December 2025 with FDA breakthrough therapy designation; the company held $2,442.6 million in cash and investments to fund development as of December 31, 2025.